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Abstract The oculocerebrorenal syndrome of Lowe
(OCRL; MIM #309000) is an X-linked human disorder
characterized by congenital cataracts, mental retardation,
and renal proximal tubular dysfunction caused by loss-of-
function mutations in the OCRL gene that encodes Ocrl, a
type II phosphatidylinositol bisphosphate (PtdIns4,5P2)
5-phosphatase. In contrast, mice with complete loss-of-
function of the highly homologous ortholog Ocrl have no
detectable renal, ophthalmological, or central nervous
system abnormalities. We inferred that the disparate phe-
notype between Ocrl-deficient humans and mice was likely
due to differences in how the two species compensate for
loss of the Ocrl enzyme. We therefore turned our attention
to Inpp5b, another type II PtdIns4,5P2 5-phosphatase
encoded by Inpp5b in mice and INPP5B in humans, as
potential compensating genes in the two species, because
Inpp5b/INPP5B are the most highly conserved paralogs to
Ocrl/OCRL in the respective genomes of both species and
Inpp5b demonstrates functional overlap with Ocrl in mice
in vivo. We used in silico sequence analysis, reverse-tran-
scription PCR, quantitative PCR, and transient transfection
assays of promoter function to define splice-site usage and
the function of an internal promoter in mouse Inpp5b
versus human INPP5B. We found mouse Inpp5b and
human INPP5B differ in their transcription, splicing, and
primary amino acid sequence. These observations form the
foundation for analyzing the functional basis for the dif-
ference in how Inpp5b and INPP5B compensate for loss of
Ocrl function and, by providing insight into the cellular
roles of Ocrl and Inpp5b, aid in the development of a
model system in which to study Lowe syndrome.
Introduction
The oculocerebrorenal syndrome of Lowe (OCRL; MIM
#309000) is an X-linked human disorder characterized by
congenital cataracts, mental retardation, and renal proximal
tubular dysfunction (Bockenhauer et al. 2008; Charnas
et al. 1991; Kenworthy and Charnas 1995; Kenworthy et al.
1993; Suchy and Nussbaum 2009). OCRL is caused by
loss-of-function mutations in the OCRL gene (Attree et al.
1992; Leahey et al. 1993; Lin et al. 1998; Monnier et al.
2000), which encodes Ocrl, a type II phosphatidylinositol
bisphosphate (PtdIns4,5P2) 5-phosphatase (Suchy et al.
1995; Zhang et al. 1995). A previous attempt to create a
mouse model for OCRL failed when mice with a complete
loss-of-function mutation in Ocrl had no discernible renal,
ophthalmological, or central nervous system abnormalities
(Janne et al. 1998). The reference protein sequences for the
Ocrl enzyme from human (NP_000267) and mouse
Electronic supplementary material The online version of this
article (doi:10.1007/s00335-010-9281-7) contains supplementary
material, which is available to authorized users.
S. P. Bothwell  A. Hoagland  R. L. Nussbaum (&)
Department of Medicine, University of California San Francisco
School of Medicine, 513 Parnassus Avenue Hse901E,
UCSF Box 0794, San Francisco, CA 94143, USA
e-mail: nussbaumr@humgen.ucsf.edu
R. L. Nussbaum
Institute for Human Genetics, University of California San
Francisco School of Medicine, San Francisco, CA 94143, USA
L. W. Farber
National Human Genome Research Institute, Bethesda,
MD 20892, USA
L. W. Farber
The George Washington University Graduate School
of Biological & Biomedical Sciences, Washington,
DC 20037, USA
123
Mamm Genome (2010) 21:458–466
DOI 10.1007/s00335-010-9281-7
(NP_796189) are 91% identical and 95% conserved, and
the gene in both species is highly expressed in tissues
relevant to OCRL, such as the brain and kidney (Janne
et al. 1998) (GeneCards: www.genecards.org; SOURCE_
Gene_Report: http://genome-www5.Stanford.edu). We
inferred that the difference in phenotype between Ocrl-
deficient humans and mice is likely not the result of a
divergence in the function of the OCRL/Ocrl orthologs
themselves but rather is due to differences in how the two
species compensate for loss of the enzyme. Inpp5b, another
type II PtdIns4,5P2 5-phosphatase (encoded by INPP5B in
humans and Inpp5b in mice), is the most highly conserved
paralog to Ocrl in the genomes of both species and has
functional overlap with Ocrl in mice in vivo (Bernard and
Nussbaum 2010; Janne et al. 1998). If the divergent phe-
notype in Ocrl-deficient mice and humans could be ascri-
bed to a difference in how well Inpp5b and INPP5B
compensate for loss of Ocrl function, then there should be
differences in the expression and/or primary structure of
the two orthologs in mice and humans. In this article we
show such differences do exist. We describe a distinctive
pattern of splicing of one exon (exon 7) and measure a
quantitative difference between the two species in the
activity of an internal promoter near exon 7.
Materials and methods
Northern blot analysis
Northern blot analysis was performed using Clontech
commercial mouse blots, hybridized per the manufacturer’s
instructions (Clontech Laboratories, Inc., Mountain View,
CA).
RT-PCR of mouse RNA
For mouse RNA, brain and kidneys were dissected from
mice and stored at 4C overnight in RNAlater (Ambion,
Austin, TX). RNA was isolated from tissues using Trizol
(Invitrogen, Carlsbad, CA). Human RNA used was human
brain total RNA (Ambion AM7962) and human kidney
total RNA (Ambion AM7976). RNA was converted to
cDNA using a First Strand cDNA Synthesis kit with ran-
dom primers (GE Healthcare 27-9261-01) according to the
manufacturer’s instructions. Once cDNA was made, 1 ll of
this reaction mixture was used in a standard PCR reaction
using forward primer MusF1 (GGTACCCGGAGTGGG
TTC) and reverse primer MusR (CGAGCTGTCCACAT
TAGAAA) for mouse cDNA and forward primers HsaF1
(TCCTGAATTCCTGTGGCTGT), HsaF2 (ATGGAGAA
GACAGGCTTTCG), and HsaF3 (ATGAGGAGCTTGAG
GAAGCA) and reverse primer HsaR1 (ATCTTGACCCCT
GGAGCTTT) for human cDNA. The PCR reaction began
with a 2-min hot start, followed by a six-cycle touchdown:
95C for 30 s, 66C for 30 s, and 72C for 1 min. The
annealing temperature decreased 1C in each of the six
cycles. The reaction was then carried out an additional 30
cycles, with each cycle consisting of the following: 95C
for 30 s, 60C for 30 s, and 72C for 1 min. The reaction
was then held at 72C for 7 min. The PCR products were
separated on a 2% agarose gel and visualized by ethidium
bromide.
Animals used as the source of mouse RNA were housed
and handled according to NIH Guidelines for the Care and
Use of Laboratory Animals under UCSF Protocols
AN076327 and AN81551.
Quantitative reverse-transcriptase PCR
Specific primer and probe sets were designed through
Assays-by-Design (Applied Biosystems, Foster City, CA)
for the full-length and alternative (internal promoter) human
INPP5B transcripts. For the full-length transcript, primers
were as follows: forward primer was HsaF1, reverse primer
was HsaR2, and the probe was ACCTCCGCCAATTGT,
which spans the GC-AG splice site used in the human full-
length transcript and is absent if the GT splice site is used.
For qPCR of the alternative transcript using the internal
promoter, primers were as follows: forward primer was
HsaF3, reverse primer was GAACCACACCTGCAGTG
TTG, which spanned the GT-AG splice site used in the
alternative transcript and is absent if the GC splice site is
used, and the probe was AAATGTCTGCCGCCGCCG,
which is present in exon 1 of the alternative transcript but is
part of intron 7 and therefore absent from the mature mRNA
of the full-length transcript. Relative expression of the two
INPP5B transcripts was obtained versus human PGK1
(Hs99999906_m1).
Each assay was performed in triplicate following the
ABI protocol. Ten nanograms of input RNA was used per
assay. For all assays, the PCR was first held at 95C for
10 min, followed by 40 cycles of 95C for 15 s and 60C
for 1 min. The critical threshold (CT) was identified in the
linear phase of the amplification. The CT was then used for
relative quantitation analysis. Relative quantitation was
done according to the Comparative CT Method described in
Applied Biosystems User Bulletin #2 for Relative Quan-
titation of Gene Expression. Prior to analysis, each assay
was first compared to the PGK1 control to demonstrate
equal efficiency of target amplification described in User
Bulletin #2. The absolute value of the slope of log input
amount versus DCT was less than 0.1 for each assay,
indicating a similar efficiency of approximately 2 between
assays.
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In silico promoter prediction
PROSCAN ver. 1.7 (Prestridge 1995) was used to scan for
possible transcription factor sites. Using a cutoff score of
53, the program has an approximately 70% sensitivity for
recognizing primate promoter sequences and a false-posi-
tive rate of about 0.0007% per base.
Luciferase assay
To test for internal promoter function, a genomic fragment
encompassing most of mouse Inpp5b exon 7 and extending
42 bp into intron 7 (Chr4 ?strand 124,428,509–
124,428,978; NCBI37/mm9) and a similar fragment encom-
passing most of human INPP5B exon 7 and extending into
intron 7 (Chr1 -strand 38,397,369–38,397,703; CRCh37/
Hg19) were isolated by PCR and cloned separately into the
promoterless basic pGL4.10 reporter vector (Promega,
Madison, WI). pGL4.13 containing the SV40 promoter and
pGL4.10 without any cloned material served as a positive
control and a promoterless negative control, respectively.
Cotransfection with a fixed amount of pGL4.73 expressing
renilla from an SV40 promoter served as a control for
transfection efficiency. Plasmids were transfected in trip-
licate per experiment and the ratio of luciferase to renilla
activity was determined as described previously (Sotiriou
et al. 2009).
Results
Previously published Northern blot analyses using the full-
length murine Inpp5b cDNA (GenBank NM_008385) as
probe revealed that the mouse gene generates two readily
detectable transcripts in most tissues examined (Janne et al.
1998; Matzaris et al. 1998). These differ in size by
approximately 800 bp and are present in approximately
equal amounts in many tissues, including lung, liver, and
kidney, but differ in amount relative to each other in other
tissues such as brain, spleen, or testis. A review of the
reference mRNA sequences of mouse Inpp5b in NCBI
Entrez reveal two isoforms: a larger 3.826-kb transcript,
consisting of 24 exons (GenBank entry NM_008385) that
encodes a protein of 993 amino acids (GenBank entry
NP_032411), and a shorter transcript of 2.964 kb (Gen-
Bank entry AK004722) that is identical to the larger tran-
script in exons 8 through 24 but lacks exons 1–6 and the
first two thirds of exon 7. The difference between these
transcripts was confirmed experimentally by Northern
blotting: a cDNA probe containing only the first six exons
of Inpp5b detects only the larger approximately 3.8-kb
transcript (Fig. 1). The simplest explanation for these
findings is that the shorter isoform is derived from a tran-
scriptional start site at an alternative internal promoter
located within exon 7.
In another previously published Northern blot, humans,
in contrast, showed only a single approximately 4.5-kb
INPP5B transcript, including in tissues relevant to Lowe
syndrome, such as brain and kidney (Janne et al. 1998).
This transcript corresponds to GenBank entry NM_005540,
which is 4.469 kb in length and encodes a 913-residue
human Inpp5b enzyme (GenBank entry NP_005531). A
comparison of the amino acid sequence of the human
enzyme (NP_005531) and the larger of the two mouse
enzymes (NP_032411) shows a high degree of similarity
between segments encoded by exons 1–6 (90% identical,
93% conserved) and exons 9 through to the end of the gene
(88% identical and 94% conserved). However, there are
significant differences in the protein segments encoded by
exons 8 and 7. The amino acid sequences of the segments
encoded by exon 8 are the same size in both species but
only 46% identical and 57% conserved. Even more striking
is the difference in the cDNA and protein representing
exon 7. The segment of the protein encoded by human
exon 7 is 47 amino acids long while that from mouse
contains 127 amino acids, a difference of 80 amino acids
(Fig. 2a). Examination of genomic DNA and transcripts
shows that exon 7 in mouse is 381 bp long while human
exon 7 is only 141 bp (Fig. 2b). There is nucleic acid
homology not only between the first 141 bases of mouse
exon 7 and all 141 bases of human exon 7, but also
between the remaining 240 bp of mouse exon 7 and the
first 240 bp of human intron 7. The expected canonical GT
50 splice site at the beginning of mouse intron 7 is con-
served in human genomic DNA, at the ?240 position
inside human intron 7, while a noncanonical GC 50 splice
donor site that marks the end of human exon 7 is conserved
in the mouse but located within exon 7 at the orthologous
location 141 bases from the beginning of the exon. We
infer from these data that human exon 7 results from uti-
lization of the internal GC 50 site, while mouse exon 7 is
defined by a GT 50 splice site 240 bases further
downstream.
Fig. 1 Northern blot analysis of mouse RNA using the first six exons
of Inpp5b as a probe. The arrowhead marks the *4 kb expected for
the full-length transcript, while the arrow marked with an asterisk is
where the shorter transcript would ordinarily be if a full-length probe
had been used. Lane 1 heart; lane 2 brain; lane 3 liver; lane 4 spleen;
lane 5 kidney; lane 6 total embryo; lane 7 lung; lane 8 thymus; lane 9
testes; lane 10 ovary
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Fig. 2 a Alignment of
segments of human and mouse
Inpp5b enzyme encoded by
exons 7 and 8. The segments
corresponding to exons 7 and 8
are shaded as indicated.
b Alignment of human and
mouse exons 7, the portion of
human intron 7 homologous to
mouse exon 7, and exon 8.
Segments are shaded with the
same patterns used in a,
indicating the various portions
of exon 7 and exon 8. The
location of primers discussed in
the text is shown. The bent
arrow indicates the approximate
location of the transcriptional
start of the transcripts generated
from the internal promoter in
mouse exon 7 and the analogous
region in human intron 7
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We confirmed the difference in splice donor site usage
in the two species by reverse transcriptase PCR (RT-PCR).
For the mouse, we chose a forward primer (MusF1) located
at the beginning of exon 7 and a reverse primer (MusR) in
exon 8 (Fig. 2b). For the human, we used three human-
specific forward primers (HsaF1, HsaF2, and HsaF3) and
one reverse (HsaR1) PCR primer. Primer HsaF1 is
upstream of the GC splice site in exon 7 (Fig. 2b), HsaF2 is
situated in human intron 7 just downstream of the GC 50
splice site, and HsaF3 is located further down in human
intron 7 in the region just upstream of the GT dinucleotide
that is homologous to the 50 splice site used by the mouse.
HsaR1 is in exon 8.
RT-PCR of mouse brain and kidney RNA using MusF1
and MusR generated only the 297-bp fragment expected if
the GT splice site were used and never the much smaller
fragment corresponding to splicing at the GC site (Fig. 3a).
In contrast, RT-PCR of human brain or kidney RNA with
the human HsaF1 and HsaR1 primers produced only a 186-
bp fragment, as expected if splicing occurred exclusively at
the GC site, and not the larger 426-bp product that would
be predicted if splicing in humans occurred at the GT 50
splice site within intron 7 (Fig. 3b, c). To confirm this
result, we used RT-PCR with a second forward primer
(HsaF2) located immediately downstream of the GC splice
site. RT-PCR with HsaF2 and HsaR1 failed to generate any
product in human brain or kidney RNA (Fig. 3b, c),
thereby demonstrating that the GC 50 splice site and not the
downstream GT site, which corresponds to the site used
exclusively by the mouse, is always used when exon 7 is
transcribed in these tissues. The failure to detect a fragment
with HsaF2-HsaR1 was not the result of nonfunctional
primers since a product of the correct size was seen using
as template an artificial cDNA construct (labeled artificial
ex7 ? 8 in Fig. 3) containing a segment of genomic DNA
that included all of human exon 7 plus the first 240 bp of
intron 7 ligated to a segment of genomic DNA containing
exon 8.
Given the absence of any RT-PCR product from human
RNA using primers HsaF2 and HsaR1 (Fig. 2b), we were
surprised to find that a third pair of primers, HsaF3-HsaR1,
did give an RT-PCR product of 145 bp in human brain and
kidney RNA (Fig. 3b, c). The product was sequenced and
shown to be cDNA sequence from the distal portion of the
first 240 bp of human intron 7, showing homology to
mouse exon 7 joined to exon 8. This product was therefore
the product of splicing at the GT dinucleotide homologous
to the mouse 50 splice site. We reasoned that this RT-PCR
product from human intron 7 could not be due to a full-
length human transcript in human that mimicked mouse
splicing because the HsaF1-HsaR1 RT-PCR product was
only 194 bp, indicating that only the GC 50 splice site was
being used, and no RT-PCR product was seen using primer
pair HsaF2-HsaR1. We therefore concluded that, like the
smaller transcript in mouse that was detectable by Northern
blot analysis, a smaller transcript was also made in humans
that had not been previously detected by Northern blot
analysis. This transcript likely initiated at an internal pro-
moter located within the first 240 bp of intron 7 and then
utilized the GT dinucleotide homologous to the mouse 50
splice site to splice onto exon 8. Indeed, an examination of
human INPP5B transcripts in GenBank reveals a 757-bp
Fig. 3 a Semiquantitative reverse transcriptase PCR of murine brain
(B) and kidney (K) RNA using primers MusF1 and MusR for 25, 30,
and 35 cycles. A 50-bp DNA ladder is shown on the left with the 200-
and 350-bp fragments labeled for orientation purposes. Only a 297-bp
fragment corresponding to splicing at the GT splice site was seen with
RT-PCR of mouse Inpp5b using MusF1 and MusR primers. b Reverse
transcriptase PCR of human brain RNA using primers HsaF1, HsaF2,
and HsaF3 and reverse primer HsaR1. A 50-bp DNA ladder is shown
on the left with the 200- and 350-bp fragments labeled for orientation
purposes. A negative control in which the reverse transcriptase was
omitted (-RT) is shown. A 192-bp fragment corresponding to splicing
at the GC splice site was seen with HsaF1 and HsaR1 primers, while a
146-bp fragment was seen with HsaF3 and HsaR1. PCR of an
artificial DNA construct, ex7 ? ex8, which consists of a segment of
genomic DNA containing human exon 7 and the first 240 bp of intron
7 ligated to a segment of genomic DNA containing exon 8, is shown
as a positive control for all three forward human primers, particularly
HsaF2. c Same as B except kidney RNA was used
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isoform (AK022846) as well as ten expressed sequence
tags (Supplementary Table 1) in which the 50 ends of the
transcripts contain sequence from intron 7 spliced onto
exon 8. A diagram summarizing all the RT-PCR results for
exons 7 and 8 in INPP5B and Inpp5b is shown in Fig. 4.
The region in mouse exon 7 and human intron 7 con-
taining the putative internal promoter is GC rich and con-
tains numerous transcription factor binding sites. A
promoter scan of the forward strand (Proscan 1.7) gave a
promoter score of 98.89 in humans and 74.73 in mice, far
above the cutoff score of 53 in both species. We therefore
decided to test this segment of DNA for promoter function
in a transient transfection assay with a luciferase reporter.
Promoter activity of a segment from either the 30 end of
mouse exon 7 or the homologous human intron 7 sequence
was assessed in a transient luciferase assay. Segments from
both species had promoter activity equal to or exceeding
the SV40 promoter in the control pGL4 luciferase vector
(Fig. 5). The approximate location of the transcriptional
start based on GenBank entries AK022846 for human and
AK004722 in mouse is shown in Fig. 3, but the diagram is
only an approximation since actual transcript mapping of
the start of transcription has not been done.
Because the human INPP5B alternative transcript made
from the internal promoter was seen only by a sensitive
RT-PCR method and not on Northern blot analysis, we
used quantitative RT-PCR (qRT-PCR) to measure more
accurately the amount of alternative transcript made from
the internal promoter relative to the full-length transcript in
humans. Real-time qRT-PCR assays using primers and
probes (TaqMan, Applied Biosystems) specific for the
full-length human transcript and the shorter alternative
transcript showed that the alternative transcript was a
minor transcript in most tissues (Fig. 6). Except for testis
and spleen, in which the shorter transcript was 50 and 20%
of total INPP5B, respectively, it constituted only about
5–10% of total INPP5B mRNA in lung, liver, and retina,
and about 3% or less of total INPP5B in such tissues as
brain and kidney that are relevant to Lowe syndrome. This
explains why the shorter alternative transcript was difficult
to visualize on Northern blot analysis of human mRNA.
The low abundance of this transcript contrasts with what is
seen in mouse, where there is sufficient transcript origi-
nating from the internal promoter to allow the smaller
transcript to be readily detected on Northern blot in a
number of tissues.
Fig. 4 Diagram summarizing
the RT-PCR results with the
location of the various primers
shown in mouse and human
exons 7 and 8. The expected
size of each product is shown
in b
Fig. 5 Luciferase activities in arbitrary units compared to the renilla
transfection control. Results are from two independent experiments,
each of which was performed in triplicate. Error bars are standard
deviations between the experiments
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Discussion
In seeking to explain the phenotypic disparity between
mice lacking Ocrl, which are normal, and humans lacking
OCRL, who have Lowe syndrome, we eliminated inter-
species differences in the OCRL/Ocrl genes themselves.
First, the human and mouse OCRL/Ocrl orthologs are 91%
identical and 95% similar at the amino acid level. Both are
expressed highly in nearly all tissues except lymphocytes
in both species (Janne et al. 1998; Olivos-Glander et al.
1995). The only alternative splicing is conserved in the two
species, resulting in inclusion or exclusion of a highly
homologous 24-base exon (NM_000276.3 and
NM_0001587.3, respectively, in human, NM_177215.3
and numerous ESTs, respectively, in mouse) located at the
same position in the mRNA. There is also a highly unusual
splice acceptor site, an AT, at the 30 end of intron 2 in both
human and mouse in OCRL and Ocrl that serves as
acceptor for a canonical GT 50 splice donor. Otherwise,
OCRL and Ocrl splicing is constitutive, uses canonical
sites, and generates exons of identical size in both species.
In contrast, the autosomal paralogs, mouse Inpp5b and
human INPP5B, which are the closest paralogs to Ocrl in
the genome with many structural motifs in common with it,
differ in a number of ways that might explain why the two
species compensate for an Ocrl enzyme deficiency differ-
ently. INPP5B and Inpp5b are the only PtdIns 5-phospha-
tases to have a Rho-GAP domain along with the shared
inositol phosphate 5-phosphatase domain. The rho-GAP
domain is noncatalytically active but has affinity for the
Rac (Faucherre et al. 2003) and ARF (Lichter-Konecki
et al. 2006) small G proteins. The paralogs also share a
pleckstrin-homology domain (Mao et al. 2009) and an ASH
(ASPM, SPD-2, Hydin) domain (Ponting 2006). The ASH
and Rho-GAP domains together interact with APPL1, a
Rab5 effector protein (Erdmann et al. 2007; McCrea et al.
2008), and the endosomal proteins Ses1 and Ses2 (Swan
et al. 2010). Ocrl, however, has a clathrin-binding domain
(Choudhury et al. 2005, 2009) that is absent from Inpp5b
(Erdmann et al. 2007). Inpp5b has similar intracellular
localization to Ocrl (Erdmann et al. 2007) as well as sim-
ilar, but not identical, substrate specificity for PtdIns(4,5)P2
(Janne et al. 1998; Schmid et al. 2004). Finally, although
cellular assays ex vivo suggest that Inpp5b is not capable of
complementing all of Ocrl’s functionality (Coon et al.
2009; Williams et al. 2007), genetic analysis indicates
that Ocrl and Inpp5b have overlapping function in vivo
(Bernard and Nussbaum 2010; Janne et al. 1998).
We did find differences in transcription, splicing, and
sequence between INPP5B and Inpp5b: (1) The full-length
human Inpp5b enzyme lacks 80 amino acids because a GC
splice site is used that causes 240 bp of sequence that is
evolutionarily conserved with mouse exon 7 to be treated
as intron and spliced out; (2) relative to the respective full-
length transcripts, there is a reduced amount of a shorter
alternative transcript originating from an internal promoter
in humans compared to mouse; and (3) exon 8 is more
divergent than the rest of the enzyme in the two species.
The reasons for the difference in 50 splice site utilization
between mouse Inpp5b and human INPP5B are unknown.
Among mammalian splice sites, 98.71% contain canonical
GT-AG junctions while only 0.56% has a noncanonical
GC-AG splice-site pair (Burset et al. 2001). A GC 50 splice
site is preceded by a G, as it is in the human, 97.6% of the
time, and by an A, as it is in C57Bl/6 and most inbred
mouse strains, only 1.6% of the time. Of interest, rat
(R. norvegicus) and bovine (B. taurus) Inpp5b also splice
predominantly at the GC splice site rather than the GT site
the mouse uses and both of these mammals have a G
immediately preceding the GC splice donor. However, this
difference is not sufficient to explain why mouse does not
use the internal GC 50 donor because sequencing of 12
inbred strains of mice revealed that AKR/J mice and their
descendants have a G preceding the internal GC splice site
and yet still do not use this splice site in liver, brain, and
kidney mRNA (data not shown). Thus, the exclusive use of
the downstream GT splice site by mouse seems unique to
the mouse and not present in human, bovine, and rat
species.
Conversely, at the GT 50 splice site utilized by mice,
both humans and mice have the typical CAG immediately
preceding the 50 splice site, both have the canonical GT at
positions ?1 and ?2, both have the highly preferred (82%)
G at the ?5 position, and neither has the preferred A or G
at ?3 or the preferred A at ?4 (Cartegni et al. 2002). The
Analyzer Splice Tool, which calculates scores for 50 and
30 splice sites (Shapiro and Senapathy 1987), gives very
comparable scores for the mouse GT 50 splice site and the
Fig. 6 Quantitative RT-PCR of the full-length and alternate human
transcripts of INPP5B in human tissues. Lu lung; Li liver; Sp spleen;
Te testis; Re retina; Br brain; Ki kidney; Ov ovary. Error bars are
standard deviations across replicates
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analogous human site of 79.78 and 73.91, respectively. The
human GT 50 splice site can clearly be functional since it is
used to generate the shorter alternative transcript in
humans. Conversely, the human GC 50 splice site and the
analogous mouse GC dinucleotide from the AKR/J mice
have comparable scores of 69.73 and 68.92, although the
score when the GC is preceded by an A, as it is in most
inbred mouse strains, is much less. Thus, the immediate
contexts around the GT and GC 50 splice sites are not
significantly different between the two species and do not
explain the difference in splice-site usage. Furthermore, the
30 splice sites at the end of intron 7 also have comparable
scores of 83.32 and 88.37, respectively, in human and
mouse. Finally, intron sizes are large in both species
(25,649 in mouse and 40,459 in human) and therefore
provide no restraint on the utilization of the GT splice site
in humans. Despite the lack of clear sequence differences
that would explain the preference for the GC versus the GT
50 splice site in human INPP5B, the phenomenon is a cis
and not a trans effect since human INPP5B integrated into
the mouse genome on a bacterial artificial chromosome in a
transgenic mouse (R. L. Nussbaum, unpublished) shows
the same overwhelming preference for the GC splice site
(Supplementary Fig. 1).
The biochemical and cellular functional consequences of
the interspecies differences between the human and mouse
orthologs of Inpp5b remain to be elucidated. Nonetheless,
they represent a significant interspecies difference in a
potential modifying paralog for Ocrl that might explain why
Inpp5b and INPP5B differ in their ability to compensate for
loss of Ocrl function. These results set the stage for inves-
tigating which of the differences are responsible for the
disparate phenotype in Ocrl-deficient humans and mice,
which may, in turn, provide additional insights into the
pathogenesis of Lowe syndrome in humans.
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